However, another recent paper cautioned that in patients with severe forms of COVID-19, who are exposed to the risks of lactic acidosis and ketoacidosis, metformin and sodium-glucose co-transporter-2 (SGLT2) inhibitors should be discontinued (55). The gene discussed is SLC5A2; the disease is COVID-19.